1001667-23-7

Basic information

• Product Name: ACH 0141625
• Synonyms: ACH 0141625;Sovaprevir;Fonadelpar;(2S,4R)-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-1-[(2S)-3,3-dimethyl-2-(2-oxo-2-piperidin-1-ylethyl)butanoyl]-4-(7-methoxy-2-phenylquinolin-4-yl)oxypyrrolidine-2-carboxamide
• CAS NO: 1001667-23-7
• Molecular Formula: C₄₃H₅₃N₅O₈S
• Molecular Weight: 799.97462
• Mol File: 1001667-23-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ACH 0141625(CAS DataBase Reference)
• NIST Chemistry Reference: ACH 0141625(1001667-23-7)
• EPA Substance Registry System: ACH 0141625(1001667-23-7)

Safety Data

• Hazardous Substances Data: 1001667-23-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ACH 0141625 is used as an anti-inflammatory and immunosuppressive agent for its ability to inhibit the production of inflammatory cytokines and suppress overactive immune responses in autoimmune diseases.
Used in Oncology:
ACH 0141625 is used as an anticancer agent for its potential to inhibit the growth of cancer cells, making it a promising compound for the development of novel therapeutics for various types of cancer.
Used in Drug Development:
ACH 0141625 is used as a lead compound in the development of novel therapeutics for inflammatory and autoimmune diseases, as well as cancer, due to its potent and selective inhibition of Janus kinase 1 (JAK1).

Upstream product

• 210048-06-9 (S)-4-(tert-butoxy)-2-(1,1-dimethylethyl)-4-oxobutanoic acid 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 630421-49-7 (1R,2S)-1-amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide hydrochloride 
• 630421-48-6 tert-butyl ((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)carbamate 

Relevant articles and documents

4-amino-4-oxobutanoyl peptides as inhibitors of viral replication

The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.

NOVEL PROCESSES FOR PRODUCING SOVAPREVIR

The disclosure includes novel processes for producing Sovaprevir comprising adding compound E to F-1 to provide Sovaprevir. The disclosure further includes intermediates useful for producing Sovaprevir. The disclosure also includes a novel crystalline form of Sovaprevir, Form F, and a method for preparing spray-dried amorphous Sovaprevir from crystalline Form F.